Print ISSN:-2249-8176

Online ISSN:-2348-7682

CODEN : PJMSD7

Current Issue

Year 2024

Volume: 14 , Issue: 2

  • Article highlights
  • Article tables
  • Article images

Article Access statistics

Viewed: 514

Emailed: 0

PDF Downloaded: 469


Ranjan, Kumar, Kumar, Hameed, Shakur, Mohan, and Dikshit: Drug utilization study and adverse drug monitoring of antidepressant drugs in a tertiary care hospital of Bihar


Introduction

Depressive disorders are amongst the most prevailing causes of morbidity and disability in the Indian population. They are generally accompanied by negative thinking, sense of guilt or worthlessness, reduced interest to work, psychomotor anxiety, unhappy married life due to reduced libido, weight loss or gain because of altered eating patterns, etc.1 They are also accompanied by other medical conditions such as chronic pain and ischemic heart disease.2 Antidepressants are primarily used for the management of depressive disorders and many anxiety disorders. However, these are also used in the pharmacotherapy of a range of psychiatric disorders including obsessive-compulsive disorders, attention deficit hyperactivity disorder, eating disorders, personality disorder, impulse control disorders, enuresis, chronic pain, neuropathic pain, etc. irrespective of the existence of co-morbid depression in these situations.3, 4 Choosing suitable antidepressants for a particular patient depends on many factors like; patient’s demographic profile, comorbidities, side-effects of the drugs, and cost-effectiveness. In the last decade, there has been a gradual shift in the prescribing patterns of antidepressants from tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAO inhibitors) to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitor (SNRIs).5 The study of prescriptions can thus help in identifying the drug utilization pattern of these antidepressants. Drug utilization studies have been defined by the World Health Organization (WHO) as marketing, distribution, prescription, and use of drugs in a society, with consideration of its medical, social and economic consequences.6 It has been estimated by WHO that depressive disorder will become the second most leading cause of morbidity and disability by the end of the year 2020.7 In addition to this, the proliferation of new drugs, increasing recognition of delayed adverse effects and the increased focus in pharmacovigilance has stimulated interest in the study of prescription patterns.8 Therefore, keeping these facts into consideration, we planned was to study the drug utilization of antidepressant drugs and their adverse drug reaction in the department of psychiatry of a tertiary care hospital.

Materials and Methods

It was an observational, prospective study done on patients visiting the outpatient department (OPD) of Psychiatry in a tertiary health care centre. The study was conducted for a duration of 18 months, i.e., from February 2018 to July 2019. The first six months were for recruitment of patients and 12 months were for follow up and data compilation. The prescriptions of every alternate patient were collected on a twice-weekly basis. The study was commenced after getting approval from Institutional Ethics Committee.

Inclusion criteria

  1. Patients of depressive disorder (diagnosed as per the International Classification of Diseases – ICD 10 criteria) 9 visiting O.P.D. of the psychiatry department.

  2. Patients between 12 to 60 years of age

  3. Patients of either gender

  4. Patients receiving antidepressant drugs

Exclusion criteria

  1. Patients below 12 years and above 60 years of age.

  2. Prescriptions without any antidepressant drugs.

  3. Patients suffering from malignancies and terminally ill patients.

  4. Patients who were judged clinically to be at a suicidal risk.

  5. Patients who had a history of substance abuse.

  6. Patients taking antidepressant drugs, prescribed from outside of our hospital.

In six months, approximately 2840 patients attended the OPD of psychiatry. Approximately 947 patients visited the OPD on our days of visit (twice weekly). In the recruitment phase, after interviewing every alternate patient, we gathered prescriptions of 473 patients. Of these 473 patients, 71 patients were ruled out as per the exclusion criteria. In the follow up period, 205 patients were lost to follow up. So finally, we were left up to 197 patients. In the follow up phase, patients were screened for suspected ADRs and were consequently reported to the adverse drug reaction monitoring centre (AMC), Department of Pharmacology of our Institute.

Prescriptions were analysed on the basis of:

  1. Age distribution.

  2. Gender distribution.

  3. Age group based utilisation of antidepressant drugs.

  4. The prescribed drugs were classified according to the Anatomical Therapeutic Chemical (ATC) and Defined Daily Dose (DDD) Classification.

  5. The Prescribed Daily Dose (PDD) was calculated by taking the average of the daily doses of psychotropic drugs. Then the PDD to DDD ratio was calculated.

Results

In our study, 21–30 years of age group accounted for the majority (31.98%) of all depressive disorders [Table 1]

Table 1

Distribution of patients on basis of age group         

Age Group

Number of patients (%) (n = 197)

12-20

14 (7.11)

21-30

63 (31.98)

31-40

43 (21.82)

41-50

50 (25.38)

51-60

27 (13.70)

In gender based analysis we found that males were more affected than females. [Table 2]

Table 2

Distribution of patients on basis of gender         

Gender

Number of patients (%) (n=197)

Male

103 (52.28)

Female

94 (47.72)

In our study, among antidepressants, SSRIs (73.26%) were most frequently prescribed, followed by TCA i.e. nortriptyline (20%) and SNRI i.e. venlafaxine (6.33%). [Table 3]   

Table 3

Age group based utilisation of antidepressant drugs

Name of Drug

Number of patients (%)

12-20 years

21-30 years

31-40 years

41-50 years

51-60 years

Fluvoxamine

37 (7.55)

3

14

10

7

3

Paroxetine

49 (10)

0

1

5

27

16

Sertraline

113 (23.06)

12

44

24

21

12

Fluoxetine

103 (21.02)

8

40

30

18

7

Nortriptyline

98 (20)

8

38

30

16

6

Venlafaxine

33 (6.73)

5

12

7

6

3

Escitalopram

57 (11.63)

3

14

8

16

16

Total

490 (100)

39

163

114

116

63

The most commonly reported ADR was insomnia (21.23%) followed by dizziness (12.33%) and weight gain (10.96%). ADRs were more commonly found in nortriptyline; a tricyclic antidepressant drug. [Table 4]

Table 4

Suspected ADRs of antidepressant drugs

ADRs

Drugs

Total (%)

Fluvoxamine

Paroxetine

Sertraline

Fluoxetine

Nortriptyline

Venlafaxine

Escitalopram

Weight Gain

16 (10.96)

-

3

-

-

6

-

7

Sedation

9 (6.16)

-

1

4

4

-

-

-

Dizziness

18 (12.33)

3

3

6

6

-

-

-

Insomnia

31 (21.23)

-

-

8

7

6

-

10

Headache

16 (10.96)

2

3

2

2

7

-

-

Akathisia

2 (1.37)

-

-

-

-

-

-

2

Tremor

2 (1.37)

-

-

-

-

-

2

-

Fatigability

11 (7.53)

-

-

-

-

11

-

0

Anorexia

9 (6.16)

1

2

4

2

-

-

-

Sexual Dysfunction

4 (2.74)

-

1

1

-

-

2

-

Nausea

11 (7.53)

1

-

3

2

3

1

1

Abdominal Pain

9 (6.16)

4

-

1

1

2

1

-

Constipation

6 (4.11)

-

-

-

-

3

3

-

Rash

2 (1.37)

-

-

-

-

2

-

-

Total

146

11

13

29

24

40

09

20

ADR/Drug

0.30

0.30

0.26

0.26

0.23

0.41

0.27

0.35

In our study, PDD/DDD values of most of the drugs were close to one which signifies that drugs were not under-utilized or over-utilized. [Table 5]

Table 5

ATC/DDD classification, PDD values and PDD/DDD ratio of antidepressantdrugs

Drugs

ATC Code

DDD

PDD

PDD/DDD

Fluvoxamine

N06AB08

100

85

0.85

Paroxetine

N06AB05

20

17.5

0.875

Sertraline

N06AB06 

50

80

1.6

Fluoxetine

N06AB03 

20

25

1.25

Nortriptyline

N06AA10 

75

79

1.05

Venlafaxine

N06AX16

100

77

0.77

Escitalopram

N06AB10

10

13.5

1.35

PDD/DDD value of sertraline, fluoxetine and nortriptyline was greater than 1. PDD/DDD values of most of the drugs were less than one and close to one.

Discussion

In our study, 21–30 years of age group accounted for the majority (31.98%) of all depressive disorders and is in accordance with several other studies, including by Dutta et al. who found that 68 patients (57.62%) were <30 years of age and 50 (42.37%) were >30 years 10, 11, 12 followed by 41-50 years (25.38%), followed by 31-40 years (21.82%), followed by 51-60 years (13.70%) and 12-20 years (7.11%). In a survey done by Kessler et al., median and inter-quartile range (IQR) of age of onset was very early for some anxiety disorders (7-14, IQR: 8-11) and impulse control disorders (7-15, IQR: 11-12). The age-of-onset distribution was later for mood disorders (29-43, IQR: 35-40), other anxiety disorders (24-50, IQR: 31-41), and substance use disorders (18-29, IQR: 21-26).11 In gender based analysis we found that males were more affected than females.13, 14 In our study, among antidepressants, SSRIs (73.26%) were most frequently prescribed, followed by TCA i.e. nortriptyline (20%) and SNRI i.e. venlafaxine (11.63%). Among SSRIs present drug utilisation was most in sertraline (23.06%) followed by fluoxetine (21.02%), escitalopram (11.63%), paroxetine (10%) and, fluvoxamine (7.55%). SSRI is the extensively prescribed antidepressants as they are generally free of sedative effects, safer at higher doses and have better tolerability with mild adverse effects.15 In many other studies, including Tripathi et al. SSRIs accounted for majority of the prescribed antidepressants. 16, 17, 18, 19

A total of 490 antidepressant drugs were prescribed in 197 prescriptions. The average number of drugs per prescription was 2.49. It is somehow in conformity with the study of Lahon et al. and Piparva et al who acclaimed 2.32 and 2.96 average number of drugs per prescriptions in their study.20, 10 Polypharmacy can lead to poor compliance, drug interactions, adverse drug reactions, and medication errors.21, 22 Since no prescription had more than five drugs, we can say that polypharmacy was avoided. In our study 146 ADRs were found in 197 patients. Most commonly reported ADR was insomnia (21.23%) followed by dizziness (12.33%) and weight gain (10.96%). ADRs were more commonly found in nortriptyline; a tricyclic antidepressant drug.23, 24

Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a drug used for its indication in adults.25 The prescribed daily dose (PDD) is the average dose, prescribed according to a representative sample of prescriptions. It is important to relate the PDD to the diagnosis on which the dosage is based. The PDD will give the average daily amount of a drug that is actually prescribed. PDD is especially important for drugs where the recommended dosage differs from one indication to another. When there is a substantial discrepancy between the PDD and DDD, it is imperative to take this into consideration when evaluating and interpreting drug utilization figures, particularly in terms of morbidity.26 The ratio of PDD to DDD is often used as an indication of the adequacy of dosing. When this ratio is either less than or greater than one, it may indicate that there is either under or over utilization of drugs. Nevertheless, it is important to note that the PDD can vary as per patient and disease factors. In our study, PDD/DDD values of most of the drugs were close to one which signifies that drugs were not under-utilized or over-utilized.

The limitation of our study was that we did not study the appropriateness of prescribing antidepressant drugs with regard to diagnosis and comorbidities. We were not able to study certain factors, such as; patient compliance, patient care indicators, adherence to treatment guidelines, and cost, which can broaden the utility of a study. Further, in our study patients of depression with psychotic symptoms, elderly depressed patients, and patients in the child and adolescent age group were excluded. Future studies should try to overcome these limitations.

Conclusion

This study was a sincere attempt to see the drug utilization of antidepressants and their ADRs. We found that SSRIs were the most commonly prescribed group of antidepressants because of their better efficacy, safety, tolerability, and fewer side effects as compared to TCAs. Among SSRIs sertraline was most frequently prescribed. The average number of drugs per prescription was 2.49. Since no prescription had more than five drugs; we can say that polypharmacy was avoided. ADRs were more frequently found in nortriptyline; a tricyclic antidepressant group.

Acknowledgement

We are thankful to the doctors of psychiatry department of IGIMS, Patna for their support.

Sources of Funding

Nil.

Conflicting Interest

Nil.

References

1 

J M Donnell R C Shelton Brunton LL Drug therapy of depression and anxiety disordersGoodman and Gilman’s The Pharmacological basis of therapeutics, 12th edn.Mc Graw HillNew Delhi2011397442

2 

De Battista C B G Katzung Antidepressant agentBasic and Clinical Pharmacology, 13th edn.Mc Graw HillNew Delhi201551030

3 

B J Sadock V A Sadock P Ruiz Kaplan Sadock Selective serotonin reuptake inhibitorsSynospsis of psychiatry, 11th edn.Philadelphia: Wolter Kluver20153190205

4 

A Avasthi S Grover M Aggarwal Research on antidepressants in IndiaIndian J Psychiatry20105273415410.4103/0019-5545.69263

5 

A Memon K Patel Drug use pattern of antidepressant agents in psychiatric patients: A prospective studyNHL J Med Sci201322

6 

S Schneeweiss A R Patrick D H Solomon J Mehta C Dormuth M Miller Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in AdultsArch General Psychiatry201067549750610.1001/archgenpsychiatry.2010.39

7 

I Banerjee B Roy I Banerjee B Sathian M Mondal A Saha Depression and its Cure: A Drug Utilization Study from a Tertiary Care Centre of Western NepalNepal J Epidemiol2011151445210.3126/nje.v1i5.6152

8 

PD Stolley L Lasagna Prescribing patterns of physiciansJ Chronic Dis1969226-739540510.1016/0021-9681(69)90003-4

9 

Patterns of psychotropic drug prescription for US patients with the diagnoses of bipolar disordersPsychiatr Serv2007588591

10 

KG Piparva AP Singh HR Trivedi DM Parmar MV Gajera Drug utilization study of psychotropic drugs in outdoor patients in a teaching hospitalIndian J Psychol Med201133154810.4103/0253-7176.85396

11 

R C Kessler M Angermeyer J C Anthony Der Graaf K Demyttenaere I Gasquet Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey InitiativeWorld Psychiatry2007616876

12 

S B Dutta DC Dhasmana R Bhardwaj Psychotropic drug utilization pattern among patients with schizophreniaIndian J Psychiatry2005474243410.4103/0019-5545.43066

13 

S Rode R Ajagallay H Salankar U Sinha A study on drug prescribing pattern in psychiatry out-patient department from a tertiary care teaching hospitalInt J Basic Clin Pharmacol2014335172210.5455/2319-2003.ijbcp20140620

14 

S Grover A Avasthi V Kumar P Kulhara An audit of first prescription of new patients attending a psychiatry walk-in-clinic in north IndiaIndian J Pharmacol20124433192510.4103/0253-7613.96302

15 

C D Battista BG Katzung Antidepressant agentsBasic and Clinical Pharmacology, 14th edn.Boston: McGraw-Hill201747588

16 

N Uchida M Y Chong C H Tan H Nagai M Tanaka M S Lee International study on antidepressant prescription pattern at 20 teaching hospitals and major psychiatric institutions in East Asia: Analysis of 1898 cases from ChinaPsychiatry Clin Neurosci2007615228

17 

ME Hemels G Koren TR Einarson Increased Use of Antidepressants in Canada: 1981–2000Psychiatry Psychiatry 20023691375910.1345/aph.1a331

18 

DG Hansen J Søndergaard W Vach L Freng Gram J-U Rosholm J Kragstrup Antidepressant drug use in general practice: inter-practice variation and association with practice characteristicsEur J Clin Pharmacol2003592143910.1007/s00228-003-0593-3

19 

A Tripathi A Avasthi A Desousa D Bhagabati N Shah RA Kallivayalil Prescription pattern of antidepressants in five tertiary care psychiatric centres of IndiaIndian J Med Res 201614345071310.4103/0971-5916.184289

20 

K Lahon H Shetty A Paramel G Sharma A Retrospective Drug Utilization Study of Antidepressants in the Psychiatric Unit of a Tertiary Care HospitalJ Clin Diagn Res20115106975

21 

A Nobili S Garattini P M Mannucci Multiple Diseases and Polypharmacy in the Elderly: Challenges for the Internist of the Third MillenniumJ Comorb201111284410.15256/joc.2011.1.4

22 

R L Bushardt E B Massey T W Simpson J C Ariail K N Simpson Polypharmacy: Misleading, but manageableClin Interv Aging200833839

23 

S Mishra T R Swain M Mohanty Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospitalJ Clin Diagn Res2013711314

24 

S Sen SK Tripathi SS Chatterjee N Era M Ghosal S Mukherjee Adverse drug reaction monitoring of antidepressants in the psychiatry out patient department at a tertiary care teaching hospital in India: A cross-sectional observational studyEur J Psychol Educ Stud20152114910.4103/2395-2555.161417

25 

Defined Daily Dose (DDD) [Internet]. World Health Organization2020https://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/en

26 

M Smalbrugge LK Jongenelis AM Pot ATF Beekman JA Eefsting Pain among nursing home patients in the Netherlands: prevalence, course, clinical correlates, recognition and analgesic treatment – an observational cohort studyBMC Geriatr200771310.1186/1471-2318-7-3



jats-html.xsl

© 2020 Published by Innovative Publication Creative Commons Attribution 4.0 International License (creativecommons.org)